Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEMTRADA vs ARZERRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alemtuzumab is a humanized monoclonal antibody that binds to CD52, a protein expressed on the surface of mature lymphocytes (T and B cells) and to a lesser extent on monocytes, macrophages, and NK cells. Binding to CD52 induces antibody-dependent cell-mediated cytolysis and complement-mediated lysis, resulting in prolonged depletion of circulating lymphocytes.
Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.
Treatment of relapsing forms of multiple sclerosis (MS), for patients who have had an inadequate response to two or more drugs indicated for MS.,Treatment of B-cell chronic lymphocytic leukemia (B-CLL) (off-label in many regions due to regulatory changes).
Treatment of chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab,Treatment of previously untreated CLL in combination with chlorambucil,Treatment of relapsed CLL in combination with fludarabine and cyclophosphamide
12 mg/day intravenously over 4 hours on 5 consecutive days (total 60 mg), followed by 12 mg/day intravenously over 4 hours on 3 consecutive days (total 36 mg) 12 months later.
ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.
12.7 days (range 7.7–22.1 days) after multiple doses; clinically relevant for prolonged lymphocyte depletion.
Mean terminal elimination half-life after first dose is approximately 14 days (range 7–21 days) and increases with repeated dosing due to target-mediated clearance saturation; at steady state, half-life is ~24 days.
Alemtuzumab is a monoclonal antibody; it is not metabolized by cytochrome P450 enzymes. Clearance occurs via intracellular catabolism and proteolytic degradation.
Ofatumumab is a monoclonal antibody; metabolism is not through typical cytochrome P450 pathways. Clearance involves catabolism to peptides and amino acids.
Renal (primarily via catabolism to peptides and amino acids, minimal intact drug in urine). No specific biliary or fecal elimination data.
Arzerra (ofatumumab) is eliminated primarily via the reticuloendothelial system and catabolism; renal excretion is minimal (<1% of dose as intact antibody). Biliary/fecal excretion has not been characterized, but as a monoclonal antibody, it is not significantly excreted in urine or feces.
Not determined; likely low due to monoclonal antibody nature (primarily binds to CD52 antigen).
As a monoclonal antibody, ofatumumab does not bind to plasma proteins; protein binding is negligible.
Approximately 0.1 L/kg; indicates limited extravascular distribution, primarily in serum and lymphoid tissues.
Volume of distribution (Vd) is approximately 2.5–4.5 L, approximating plasma volume; does not distribute extensively into tissues (not reported in L/kg, but typical for Ig G1 monoclonal antibodies ~0.1–0.2 L/kg).
IV only; not applicable (100% bioavailability via IV infusion).
Subcutaneous: ~60–70% absolute bioavailability; intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or hemodialysis; use with caution.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended in severe hepatic impairment (Child-Pugh C) due to lack of data.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C); use with caution.
Safety and efficacy in pediatric patients (<18 years) have not been established.
Safety and efficacy in pediatric patients (<18 years) have not been established; no recommended dosing.
No specific dose adjustment recommended; limited data available in patients ≥65 years; use with caution due to higher risk of infections and immune-mediated disorders.
No specific dose adjustment required for elderly patients. Clinical studies included patients ≥65 years; overall efficacy and safety similar to younger adults, but higher incidence of serious infections and cardiac events observed.
WARNING: SERIOUS AUTOIMMUNE CONDITIONS, INFUSION REACTIONS, AND MALIGNANCIES. Alemtuzumab can cause serious, potentially fatal autoimmune conditions (e.g., immune thrombocytopenia, glomerulonephropathies, autoimmune hemolytic anemia, autoimmune pancytopenia), infusion reactions, and an increased risk of malignancies including thyroid cancer, melanoma, and lymphoproliferative disorders. Only prescribers enrolled in a restricted distribution program should prescribe alemtuzumab.
Hepatitis B virus (HBV) reactivation can occur with ofatumumab, leading to fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before initiation. Monitor HBV carriers during and after treatment.
Autoimmune conditions: Monitor for immune thrombocytopenia, glomerulonephropathies, autoimmune hemolytic anemia, and autoimmune pancytopenia.,Infusion reactions: Premedicate and monitor; reactions can be severe.,Infections: Increased risk due to lymphopenia; monitor for Listeria, herpes, and other opportunistic infections.,Malignancies: Monitor for thyroid cancer, melanoma, and lymphoproliferative disorders.,Vaccination: Avoid live vaccines during and after treatment.,Reproductive risk: Advise women of childbearing age to use contraception during and for 4 months after treatment.
Infusion reactions (including anaphylaxis), prolonged cytopenias, progressive multifocal leukoencephalopathy (PML), intestinal obstruction, tumor lysis syndrome, and infections including hepatitis B reactivation.
Hypersensitivity to alemtuzumab or any of its excipients.,Active infection (except minor localized infections).,Known history of progressive multifocal leukoencephalopathy (PML).,Concurrent treatment with other immunosuppressive therapies (not recommended).
Known hypersensitivity (anaphylaxis) to ofatumumab or any of its excipients.
No specific food interactions. Grapefruit and other CYP450 substrates are not relevant; alemtuzumab is not metabolized by CYP enzymes. Avoid alcohol due to potential immune effects.
No known food interactions. Take with or without food.
Pregnancy category: Contraindicated in pregnancy. Alemtuzumab is an Ig G1 monoclonal antibody that crosses the placenta. First trimester: Fetal Ig G exposure begins around week 13 of gestation; prior to that, transfer is minimal. Second and third trimesters: Ig G actively transported across placenta, increasing fetal exposure. Cases of fetal harm (spontaneous abortion, fetal death) reported. Risk of profound lymphopenia and other immune alterations in the newborn. No adequate human studies; animal studies show embryolethality and developmental toxicity.
ARZERRA (ofatumumab) is a human monoclonal antibody. Ig G molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), there is a potential risk of fetal B-cell lymphocytopenia and impaired immune response. Data from animal studies are insufficient. The drug should be avoided during pregnancy unless the benefit clearly outweighs the risk.
Excreted in human milk in low amounts; M/P ratio not available. Given the high molecular weight (approx. 150 k Da) and potential for immunosuppression in the nursing infant, breastfeeding is not recommended during treatment and for at least 4 months after the last dose.
It is unknown whether ofatumumab is excreted in human milk. Human Ig G is present in breast milk, but levels are low. Due to the potential for serious adverse reactions in the breastfed infant (including B-cell depletion), breastfeeding is not recommended during therapy and for at least 6 months after the last dose. No M/P ratio is available.
Contraindicated; do not use in pregnancy. No dosing adjustment studies exist. If a woman becomes pregnant during treatment, discontinue therapy immediately and refer to high-risk obstetrics. No pharmacokinetic data are available to suggest dose changes in pregnancy; however, altered volume of distribution and clearance may occur but are not characterized.
No specific dose adjustment guidelines are established for pregnancy. The pharmacokinetics of monoclonal antibodies may be altered due to increased plasma volume and clearance in pregnancy, but no formal studies have been conducted. Use caution and consider therapeutic drug monitoring if available.
Lemtrada (alemtuzumab) is a CD52-directed cytolytic monoclonal antibody for relapsing-remitting multiple sclerosis (RRMS). Administer via IV infusion over 4 hours for 5 consecutive days (first course) and 3 consecutive days (second course, 12 months later). Premedicate with corticosteroids (e.g., methylprednisolone 1 g IV) for 3 days each course to mitigate infusion reactions. Monitor for autoimmune adverse effects: immune thrombocytopenia (ITP), thyroid disorders, nephropathies. Obtain baseline and monthly CBC, serum creatinine, urinalysis with microscopy, and thyroid function for 48 months after last dose. Vaccinate for varicella zoster virus (VZV) at least 6 weeks prior if seronegative; avoid live vaccines during and after treatment. Pregnancy category C—contraindicated in pregnancy; effective contraception required during and 4 months after treatment.
ARZERRA (ofatumumab) is a monoclonal antibody targeting CD20 used in relapsing multiple sclerosis. First dose reactions are common; premedicate with corticosteroids, antihistamines, and antipyretics. Monitor for infections, especially hepatitis B reactivation. Contraindicated in active hepatitis B. Administer as subcutaneous injection; injection site reactions frequent. Live vaccines contraindicated during and after treatment until immune reconstitution.
This drug is given as an intravenous infusion for five days in a row for the first course, and three days in a row one year later. Each infusion takes about 4 hours.,You will receive steroid medications before each infusion to reduce the risk of infusion reactions (fever, chills, rash, breathing problems).,Serious side effects include autoimmune conditions affecting blood cells (low platelets), thyroid, or kidneys. You need monthly blood and urine tests for at least four years after the last dose.,You may be at higher risk for infections; report any signs of infection (fever, cough, painful urination) immediately.,Do not receive live vaccines (e.g., chickenpox, nasal flu vaccine) during treatment and for at least 12 months after.
Report any signs of infection (fever, chills, cough, painful urination) promptly.,Inform your doctor of any history of hepatitis B infection.,You will receive premedication before the first dose to reduce allergic reactions.,Do not receive live vaccines during treatment or until your doctor confirms immune recovery.,Common side effects include injection site reactions, headache, and fever.,ARZERRA is given as an injection under the skin; rotation of injection sites is recommended.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEMTRADA vs ARZERRA, answered by our medical review team.
LEMTRADA is a Monoclonal Antibody that works by Alemtuzumab is a humanized monoclonal antibody that binds to CD52, a protein expressed on the surface of mature lymphocytes (T and B cells) and to a lesser extent on monocytes, macrophages, and NK cells. Binding to CD52 induces antibody-dependent cell-mediated cytolysis and complement-mediated lysis, resulting in prolonged depletion of circulating lymphocytes.. ARZERRA is a Antineoplastic, Monoclonal Antibody that works by Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEMTRADA and ARZERRA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEMTRADA is: 12 mg/day intravenously over 4 hours on 5 consecutive days (total 60 mg), followed by 12 mg/day intravenously over 4 hours on 3 consecutive days (total 36 mg) 12 months later.. The standard adult dose of ARZERRA is: ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEMTRADA and ARZERRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEMTRADA is classified as Category C. Pregnancy category: Contraindicated in pregnancy. Alemtuzumab is an IgG1 monoclonal antibody that crosses the placenta. First trimester: Fetal IgG exposure begins around week 13 of. ARZERRA is classified as Category C. ARZERRA (ofatumumab) is a human monoclonal antibody. IgG molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.